
Profound Medical Corp PRN.TO is expected to show a rise in quarterly revenue when it reports results on March 6 for the period ending December 31 2024
The Mississauga Ontario-based company is expected to report a 112.4% increase in revenue to $4.267 million from $2.01 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Profound Medical Corp is for a loss of 35 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Profound Medical Corp is C$24.42, above its last closing price of C$10.11.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.29 | -0.29 | -0.38 | Missed | -29.9 |
Jun. 30 2024 | -0.29 | -0.29 | -0.28 | Beat | 4.1 |
Mar. 31 2024 | -0.28 | -0.27 | -0.26 | Beat | 5.5 |
Dec. 31 2023 | -0.28 | -0.32 | -0.42 | Missed | -31.5 |
Sep. 30 2023 | -0.33 | -0.34 | -0.26 | Beat | 22.7 |
Jun. 30 2023 | -0.36 | -0.35 | -0.35 | Met | 1.4 |
Mar. 31 2023 | -0.35 | -0.36 | -0.32 | Beat | 11.1 |
Dec. 31 2022 | -0.37 | -0.46 | Missed | -24.3 |
This summary was machine generated March 4 at 21:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)